Clarkston Capital Partners LLC Sells 174,468 Shares of Ralliant Corporation $RAL

Clarkston Capital Partners LLC cut its holdings in Ralliant Corporation (NYSE:RAL) by 31.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 384,747 shares of the company’s stock after selling 174,468 shares during the period. Clarkston Capital Partners LLC’s holdings in Ralliant were worth $16,002,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Danske Bank A S purchased a new position in shares of Ralliant in the fourth quarter worth $25,000. V Square Quantitative Management LLC purchased a new position in Ralliant during the fourth quarter valued at $26,000. Allworth Financial LP grew its stake in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares in the last quarter. Palisade Asset Management LLC bought a new stake in Ralliant in the 3rd quarter valued at $26,000. Finally, BOKF NA bought a new stake in Ralliant in the 3rd quarter valued at $29,000.

Ralliant Trading Up 0.1%

Shares of RAL opened at $70.25 on Friday. The company’s fifty day simple moving average is $66.23 and its 200-day simple moving average is $53.69. The company has a market cap of $7.86 billion and a P/E ratio of -6.42. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. The company had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, analysts expect that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio is currently -1.83%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Citigroup lifted their target price on Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Barclays lifted their price objective on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Wall Street Zen upgraded Ralliant from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. BMO Capital Markets assumed coverage on shares of Ralliant in a report on Monday. They issued a “market perform” rating and a $78.00 target price for the company. Finally, Oppenheimer upped their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $73.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.